Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: FAQs Then May 10, 2012

"TPL’s rationale for not disclosing licensing terms is to avoid this information setting minimum or upper limits on future licensing deals, which would make it harder for TPL in future negotiations with prospective licensees. Potential licensees would have access to this information through Patriot’s public filings. While we understand the desire of our shareholder’s to have this detailed information, we have to agree with TPL that it is probably in the best interests of the licensing program not to disclose license details."

This is a funny quote considering the actions of TPL with regard to Apple that is now public information and may have set the "floor" from now till the end.

Share
New Message
Please login to post a reply